Literature DB >> 25481638

Can measurement of apparent diffusion coefficient before treatment predict the response to uterine artery embolization for adenomyosis?

Yaewon Park1, Man Deuk Kim, Dae Chul Jung, Shin Jae Lee, Gyoungmin Kim, Sung Il Park, Jong Yun Won, Do Yun Lee.   

Abstract

OBJECTIVES: To determine the usefulness of the apparent diffusion coefficient (ADC) in predicting response to uterine artery embolization (UAE) for symptomatic adenomyosis.
METHODS: A prospective study was performed on 25 patients who underwent diffusion-weighted (DW) magnetic resonance imaging (MRI) before UAE between June 2011 and December 2012. All patients underwent 3-month follow-up MRI after UAE using non-spherical polyvinyl alcohol (PVA) particles ranging from 150 to 500 μm. Quantitative measurement of the ADC was performed for each adenomyosis. Complete response and incomplete response were defined as ≥ 90 % or < 90 %, respectively, of the non-perfusion area with adenomyosis at the follow-up MRI. The ADC values were compared between patients who achieved complete or incomplete response which was assessed according to the MRI findings after UAE.
RESULTS: Nineteen patients showed complete response, and six showed incomplete response. The ADC value ranged from 0.842 to 1.346 × 10(-3) mm(2)/s (mean 1.075 ± 0.117). The mean ADC was 1.043 ± 0.237 in the complete response group and 1.176 ± 0.429 in the incomplete response group (0.012). Using a threshold of <1.147 × 10(-3) mm(2)/s, the sensitivity and specificity of the ADC to predict success after UAE were 83.3 % and 84.2 %.
CONCLUSION: The ADC of adenomyosis may potentially predict a successful response to UAE for adenomyosis. KEY POINTS: • Pre-procedural MRI might help clinicians predict response of UAE in adenomyosis • ADC might help predict UAE outcomes in adenomyosis • MR predictors might be used to counsel patients with symptomatic adenomyosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25481638     DOI: 10.1007/s00330-014-3504-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  26 in total

1.  Arterial embolisation to treat uterine myomata.

Authors:  J H Ravina; D Herbreteau; N Ciraru-Vigneron; J M Bouret; E Houdart; A Aymard; J J Merland
Journal:  Lancet       Date:  1995-09-09       Impact factor: 79.321

Review 2.  MR imaging findings of adenomyosis: correlation with histopathologic features and diagnostic pitfalls.

Authors:  Ken Tamai; Kaori Togashi; Tsuyoshi Ito; Nobuko Morisawa; Toshitaka Fujiwara; Takashi Koyama
Journal:  Radiographics       Date:  2005 Jan-Feb       Impact factor: 5.333

3.  Uterine artery embolization for symptomatic adenomyosis: a new technical development of the 1-2-3 protocol and predictive factors of MR imaging affecting outcomes.

Authors:  Man Deuk Kim; Yong Min Kim; Hyun Cheol Kim; Jung Hyun Cho; Hyung Gon Kang; Chan Lee; Hee Jin Kim; Jong Tae Lee
Journal:  J Vasc Interv Radiol       Date:  2011-03-05       Impact factor: 3.464

4.  Uterine artery embolization for the treatment of uterine leiomyomata midterm results.

Authors:  S C Goodwin; B McLucas; M Lee; G Chen; R Perrella; S Vedantham; S Muir; A Lai; J W Sayre; M DeLeon
Journal:  J Vasc Interv Radiol       Date:  1999-10       Impact factor: 3.464

5.  Uterine artery embolisation for symptomatic adenomyosis--mid-term results.

Authors:  M J Bratby; W J Walker
Journal:  Eur J Radiol       Date:  2008-02-15       Impact factor: 3.528

6.  Economic evaluation of uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: results from the randomized EMMY trial.

Authors:  Nicole A Volkers; Wouter J K Hehenkamp; Patrick Smit; Willem M Ankum; Jim A Reekers; Erwin Birnie
Journal:  J Vasc Interv Radiol       Date:  2008-07       Impact factor: 3.464

7.  The utility of diffusion-weighted MR imaging for differentiating uterine sarcomas from benign leiomyomas.

Authors:  Ken Tamai; Takashi Koyama; Tsuneo Saga; Nobuko Morisawa; Koji Fujimoto; Yoshiki Mikami; Kaori Togashi
Journal:  Eur Radiol       Date:  2007-10-10       Impact factor: 5.315

8.  MRI of adenomyosis: changes with uterine artery embolization.

Authors:  Yuri Kitamura; Sandra J Allison; Reena C Jha; James B Spies; Pamela A Flick; Susan M Ascher
Journal:  AJR Am J Roentgenol       Date:  2006-03       Impact factor: 3.959

Review 9.  Diffusion-weighted MRI in the body: applications and challenges in oncology.

Authors:  Dow-Mu Koh; David J Collins
Journal:  AJR Am J Roentgenol       Date:  2007-06       Impact factor: 3.959

10.  Symptomatic uterine fibroids: treatment with uterine artery embolization or hysterectomy--results from the randomized clinical Embolisation versus Hysterectomy (EMMY) Trial.

Authors:  Wouter J K Hehenkamp; Nicole A Volkers; Erwin Birnie; Jim A Reekers; Willem M Ankum
Journal:  Radiology       Date:  2008-01-09       Impact factor: 11.105

View more
  4 in total

1.  Predisposing factors for predicting the therapeutic response of adenomyosis after uterine artery embolization: serum CA125 levels and accompanying endometriosis.

Authors:  Rui Zheng; Dan Zeng; Ting-Ting Wan; Wen-Bo Guo; Yan Guo; Ming-Juan Liu
Journal:  Diagn Interv Radiol       Date:  2018-11       Impact factor: 2.630

2.  Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial.

Authors:  Annefleur Machteld de Bruijn; Wouter Jk Hehenkamp; Paul Nm Lohle; Judith Af Huirne; Jolanda de Vries; Moniek Twisk
Journal:  JMIR Res Protoc       Date:  2018-03-01

3.  Uterine Artery Embolization for Symptomatic Adenomyosis: 7-Year Clinical Follow-up Using UFS-Qol Questionnaire.

Authors:  Annefleur M de Bruijn; Marieke Smink; Wouter J K Hehenkamp; Robbert J Nijenhuis; Albert J Smeets; Focco Boekkooi; Paul J H M Reuwer; Willem J Van Rooij; Paul N M Lohle
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-17       Impact factor: 2.740

4.  Uterine Artery Embolization for Leiomyomas and Adenomyosis: A Pictorial Essay Based on Our Experience from 1300 Cases.

Authors:  Man Deuk Kim
Journal:  Korean J Radiol       Date:  2019-10       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.